Lung Cancer

The FDA approved alectinib as first-line therapy for ALK-positive non-small cell lung cancer based on results of the ALEX study, which showed significant improved PFS compared with crizotinib.

Data presented at the recent World Conference on Lung Cancer show that pembrolizumab improves overall survival in patients with metastatic non-small cell lung cancer whose tumors express high levels of PD-L1.

A new risk model was effective at identifying individuals subsequently diagnosed with early and potentially curable lung cancer.

Data presented at the ASTRO annual meeting demonstrate a benefit of radiation plus immunotherapy for patients with advanced disease, including stage IV NSCLC.

Data presented at the ASTRO annual meeting demonstrate a benefit of radiation plus immunotherapy for patients with advanced disease, including stage IV NSCLC.

This video reviews results of a randomized trial comparing intensity modulated radiation therapy vs passively scattered proton therapy for locally advanced non–small-cell lung cancer.

The combination of selumetinib and docetaxel did not improve progression-free survival among patients with advanced or metastatic non–small-cell lung cancer vs placebo plus docetaxel.

Participating in a 12-week physical exercise and psychosocial intervention improved the functional capacity of patients with advanced-stage lung cancer, which may result in improvement in quality of life, according to the results of a study presented at the World Conference on Lung Cancer.

Treating patients with early-stage, resected, node-positive non–small-cell lung cancer with customized chemotherapy based on BRCA1 expression levels did not increase overall survival rates.

Quality of life was not improved with the use of early palliative care for patients recently diagnosed with malignant pleural mesothelioma, according to data presented at the World Conference on Lung Cancer.

Small-cell lung cancer patients with high tumor mutation burden treated with immunotherapy had greater objective response rate, progression-free survival, and overall survival compared with patients with medium or low tumor burden.

While the incidence of irAEs is relatively low, the absolute number of patients receiving immune checkpoint inhibitors is steadily increasing. Thus, it is likely that, with time, larger numbers of patients will develop irAEs, including pneumonitis.

The second-generation EGFR tyrosine kinase inhibitor dacomitinib significantly improved progression-free survival over gefitinib as a first-line therapy for EGFR–positive non–small-cell lung cancer, according to a randomized phase III trial.

Data presented at the ESMO 2017 Congress demonstrated that alectinib may have CNS benefit in patients with advanced ALK-positive NSCLC.

This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.

This video highlights studies on advanced lung cancer with practice-changing potential presented at the 2017 ASTRO Annual Meeting.

Undergoing SBRT prior to starting maintenance chemotherapy significantly improved progression-free survival in patients with limited metastatic non–small-cell lung cancer, according to the results of a phase II study presented at the ASTRO Annual Meeting.

A case study from the University of Colorado suggests that traditional gene testing for NSCLC patients may not be sufficient for detecting potential oncogenic drivers.

People living with HIV who adhere to antiretroviral therapy but still smoke cigarettes are substantially more likely to die from lung cancer than from AIDS-related causes, according to the results of a new study.

Supplementation with B vitamins was associated with an increased risk of lung cancer among men, though not among women, according to a new study.

The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.

Circulating tumor cells isolated from early stages of lung cancer may be predictive of poor prognosis and could potentially be predictive biomarkers of disease recurrence.

A study comparing two options for follow-up protocol after complete lung cancer resection suggests that regular CT scans after resection may not be necessary, though there may be some benefits to these additional scans.

This video reviews the need for biomarkers and tools that could identify those at high risk of immune-related toxicities among patients undergoing immunotherapy treatment.

The programmed death 1 (PD-1) inhibitor pembrolizumab offers promising antitumor activity and a safety profile consistent with earlier research in heavily pretreated patients with programmed death ligand 1 (PD-L1)–expressing extensive-stage small-cell lung cancer, according to results of a phase I study.